By Fineline Cube 
Shenzhen Pregene Biopharma Co., Ltd. has entered into a License and Collaboration Agreement with Kite, a Gilead company, to accelerate the development of next-generation in vivo therapies. This partnership aims to expedite proof-of-concept studies and deliver breakthrough treatments, particularly in oncology and autoimmune diseases.
Financial Terms
Under the agreement, Pregene has received a non-refundable upfront payment of USD 120 million. Additionally, Pregene is eligible to receive up to USD 1.52 billion in milestone payments and sales royalties based on future net product sales.
Innovation in Therapy
The collaboration centers on in vivo editing therapy, a next-generation cell therapy that generates edited cells inside the patient’s body through a single infusion. This approach contrasts with traditional ex vivo CAR-T therapy, which involves complex cell collection procedures. The new technology significantly reduces treatment and time costs.-Fineline Info & Tech